Multiple Myeloma is a cancer characterized by the proliferation of a clone of plasma cells in the bone marrow and induces overproduction of immunoglobulins (antibody proteins) that crowd out the normal blood-forming cells and prevent them from functioning effectively.
The symptoms of Multiple Myeloma include bone lesions, anaemia, kidney damage and susceptibility to infections. Patients commonly experience bone pain and fractures, also experiencing weight loss, tiredness and repeated infections(2).
The tumour plasma cell clone proliferation induces high levels concentration of Monoclonal protein (also called M-Protein) which is the best tumour markers of the disease.
Serum and urine protein electrophoresis and their immunological characterisation are the gold standard for Multiple Myeloma diagnosis, for monitoring the disease and to assess the patient’s response to treatment.
Protein electrophoresis is recommended by IMWG (International Myeloma Working Group) for screening serum and urine samples for abnormalities protein detection(3).
Once the Monoclonal protein is identified (or suspected), it must be characterized by an immunofixation or immunotyping test to identify the M-Protein type (IgG, IgA, IgM, IgD, IgE) and light chain (kappa or Lambda) involved.
Sebia is the world leader in diagnosis and monitoring of Multiple Myeloma patient by offering a full range of solutions to enable clinicians to provide optimal medical care. Ensuring high quality results adapted to all laboratories sizes. Sebia solutions offer serum and urine proteins electrophoresis (SPE/UPE) for screening and identification (immunofixation/Immunotyping), measurement of FLC* and follow-up monoclonal antibody therapy with HYDRASHIFT portfolio.
* Under Product Registration approval
The HYDRASHIFT portfolio include IVD test to mitigate interferences seen in immunofixation result for patient treated with isatuximab or daratumumab.
The serum Free Light Chains is an important test in Prognosis and Monitoring of Multiple Myeloma patients.
With this short video report, become aware of all the benefits of partnering with Sebia and integrate your capillary electrophoresis into the lab track automation.
Immunotherapies for Multiple Myeloma, like the monoclonal antibody daratumumab, can create false positive IgG Kappa bands on Immunofixation gels. This paper describes best practice guidelines for using the Hydrashift assay to remove daratumumab interference from Immunofixation gels.
Educational Webinar with Katie Thoren, PhD, Memorial Sloan Kettering Cancer Center
Educational Webinar with Prof. Giovanni PALLADINI, PhD
Educational Webinar with Dr. Julien GUILLEMAUD
Educational Webinar with Dr. Jack Maggiore from Loyola University Medical Center in Chicago, IL
Large menu with high quality results on gel electrophoresis.
The compact and affordable automation of Capillary Electrophoresis.
The power of up to 36 capillaries in one automated high volume workcell.
Connect our flexible electrophoresis instrument on lab automation track.
Evolution makes the difference.
High throughput Serum Protein Electrophoresis, with high resolution results.
High throughput Urine Protein Electrophoresis, with high resolution results.
Proteinuria screening for renal disease.
Identification of monoclonal proteins by agarose gel electrophoresis.
Fully automated monoclonal proteins identification by Capillarys electrophoresis.
The next generation Free Light Chain Assay.
* Under Product Registration approval
Avoid interferences due to therapeutic Monoclonal Antibody with HYDRASHIFT Portfolio.
This section contains information intended for wide distribution and may therefore contain product details or information that is not available or valid in your country.
Please contact your local Sebia representative. Information intended for healthcare professionals.
Carefully read the instructions in the reagent package inserts and instrument manuals.